CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Observational cohort study on the natural history of hospitalized SARS-COV-2 patients.Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug1863 Plasma Wiki 0.58

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Observational Cohort Study on the Natural History of Hospitalized SARS-COV-2 Patients: the STORM Trial

This is an observational study. The aim is to describe the natural history and clinical evolution over time of hospitalized patients affected by Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-COV-2) infection, including the genetic pathology of the disease and improve therapeutic procedures.

NCT04424992 Sars-CoV2 Other: Observational cohort study on the natural history of hospitalized SARS-COV-2 patients.

Primary Outcomes

Description: Description over time of hospitalized patients suffering from SARS-COV-2 infection to better understand the pathogenesis of the disease and improve the controls and therapeutic procedures.

Measure: Covid19 infection clinical evolution

Time: Until patient discharge from the hospital (approximately 1 year)

Secondary Outcomes

Description: Identify risk factors for intra-hospital mortality in hospital wards COVID + patients.

Measure: Risk factors for intra-hospital mortality

Time: Until patient discharge from the hospital (approximately 1 year)

Description: Assess the impact of a fragility index (IF) on the clinical course of COVID + patients.

Measure: The impact of a fragility index (IF)

Time: Until patient discharge from the hospital (approximately 1 year)

Description: Build a prognostic score through which it is possible define a stratification that orients, according to the state of hospitalization, the therapeutic choices.

Measure: Prognostic score

Time: Until patient discharge from the hospital (approximately 1 year).

Description: Differentiate the lung sequelae related to the evolution of viral damage from those of cheater / volutrauma connected to non-invasive (NIV-CPAP) or invasive (MV) ventilation methods.

Measure: The lung sequelae of SARS-COV-2 pneumonia

Time: Until patient discharge from the hospital (approximately 1 year)

Description: Assess the accuracy of IF in elderly patients in terms of clinical outcomes compared to one clinical evaluation based on age and co-morbidity.

Measure: The accuracy of IF in elderly patients

Time: Until patient discharge from the hospital (approximately 1 year)

Description: Describe the anomalies of the coagulation system, which appear on patients affected by SARS-COV-2 pneumonia.

Measure: Coagulation system anomalies

Time: Until patient discharge from the hospital (approximately 1 year)

Description: Description of the impact of the prone position in terms of increased oxygenation of the patient suffering from SARS-COV-2 pneumonia as an index lung recruitment.

Measure: The impact of the prone position on the oxygenation

Time: Until patient discharge from the hospital (approximately 1 year)


No related HPO nodes (Using clinical trials)